Moving RDA™ to the Clinic
Rna Diagnostics (RnaDx) made significant progress in 2012 as we work to bring our cancer therapy response technology, RDA™, towards market.
-
Accrual of patients to the RDA clinical trial at Sunnybrook Hospital, Toronto is progressing well. The trial is expanding to the Jewish General Hospital and Hotel Dieu in Montreal, Quebec. Recruitment of additional sites in Ontario and Quebec continues.
-
The research collaboration with the Instituti Ospitaliere di Cremona (Drs. D. Generali and A. Bottini) on pre-existing clinical samples is underway. Samples from two clinical trials are now being analyzed at the RnaDx laboratory in Sudbury.
-
In December 2012, RnaDx participated in the San Antonio Breast Cancer Symposium which was attended by 9,000 breast cancer specialists. RDA was enthusiastically received by key opinion leaders from around the world. The Management Team met with the RnaDx Clinical Advisory Board to review recommendations on how RDA may be used to guide treatment decisions.
-
A scientific poster describing the application of RDA to radiation treatment of breast cancer was presented at the San Antonio Breast Cancer Symposium.
New Patent Filings
RnaDx recentlly filed two new patents. One is for assessment of therapeutic radiation efficacy by RDA and the other, a technology to enhance RDA identification of chemotherapy treatment response.
Business Advisory Board
RnaDx has added two new members to its Business Advisory Board. Denis Ho, former Managing Director of Life Sciences Venture Capital at the Business Development Bank of Canada, brings over 20 years of biotech start-up governance to RnaDx. Paul Lucas, former CEO of GlaxoSmithKline Canada and current chair of Life Sciences Ontario, brings in-depth pharmaceutical industry market intelligence to the company.
RnaDx Team with Cremona Collaboration in San Antonio
Dr. Maureen Trudeau, Dr. Danieli Generali, John Connolly,
Dr. Alberto Bottini, Dr. Ken Pritzker, Gino Ariano
The Management Team met with the RnaDx Clinical Advisory Board to review recommendationson how RDA may be used to guide treatment decisions.
|
|
|
